Sandoz Inc. and RareGen LLC v. United Therapeutics Corporation and Smiths Medical ASD, Inc.
In Sandoz Inc. v. United Therapeutics Corporation, Eric Gaier was retained on behalf of United Therapeutics Corporation (UTC) and Smiths Medical to testify regarding issues of market definition, market power, competitive effects, and irreparable harm. Plaintiffs Sandoz and RareGen alleged that defendants UTC and Smiths Medical blocked Sandoz from launching a generic formulation of UTC’s Pulmonary Arterial Hypertension drug, Remodulin®. Plaintiffs initially sought a preliminary injunction to access certain ambulatory infusion pumps manufactured by Smiths Medical and used to administer Remodulin® via subcutaneous injection. The District Court denied the plaintiffs’ motion for a preliminary injunction and subsequently granted the defendant’s motion for summary judgment on the antitrust allegations.